Background: SGLT-2 inhibitors (SGLT-2i) have been associated with decreased cardiovascular (CV)
morbidity and mortality in patients with type 2 diabetes (T2DM). The objective of
this study was to measure the association of SGLT-2i and other oral glucose-lowering
drugs (oGLD) on all-cause mortality in elderly patients with newly diagnosed T2DM.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
